Patents by Inventor Junbo Ge
Junbo Ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779575Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.Type: GrantFiled: August 6, 2021Date of Patent: October 10, 2023Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Junbo Ge, Aijun Sun, Jingjing Hu, Kun Yang
-
Publication number: 20220370428Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.Type: ApplicationFiled: August 6, 2021Publication date: November 24, 2022Applicant: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Junbo GE, Aijun SUN, Jingjing HU, Kun YANG
-
Publication number: 20220183694Abstract: The present invention relates to the field of medical device technologies, and more particularly, to a puncturable atrial septal occluder. The main body of the puncturable atrial septal occluder is made by heat setting after integrally weaving a memory wire material. The occluder includes a stent formed by a left disc, a right disc, and a waist connected, a large central through hole penetrating the stent, and a notch formed at the centers of the left and right discs after the penetration. A baffle membrane is provided inside the central through hole. The notch at the center of the right disc is provided with a plurality of connecting wires. One end of each of the plurality of connecting wires is converged and connected to the delivery component, and the other end of each of the plurality of connecting wires is connected to the right disc in a radioactive manner.Type: ApplicationFiled: August 18, 2021Publication date: June 16, 2022Inventors: Wenzhi PAN, Daxin ZHOU, Junbo GE
-
Patent number: 10603168Abstract: A valve clamp for treating the cardiac valve regurgitation. The valve clamp includes a first clamp part, a second clamp part, and a connecting part. The first clamp part has the first clamping arms. The second clamp part has a corresponding number of second clamping arms. The first clamping arm and the second clamping arm can clip an object therebetween through the interaction force generated by closing and pushing against each other. Moreover, the valve clamp can also include a closed ring, which is sleeved outside the periphery of the first clamp part and the periphery of the second clamp part, such that the clamping arms can close as needed, and the clamping is tighter. The valve clamp has the advantages of a minimally invasive implantation, a simple manufacture, a low difficulty of operation, good effects, etc.Type: GrantFiled: February 15, 2017Date of Patent: March 31, 2020Assignee: ZHONGSHAN HOSPITAL, FUDAN UNIVERSITYInventors: Wenzhi Pan, Daxin Zhou, Junbo Ge, Leilei Cheng
-
Publication number: 20190000623Abstract: A valve clamp for treating the cardiac valve regurgitation. The valve clamp includes a first clamp part, a second clamp part, and a connecting part. The first clamp part has the first clamping arms. The second clamp part has a corresponding number of second clamping arms. The first clamping arm and the second clamping arm can clip an object therebetween through the interaction force generated by closing and pushing against each other. Moreover, the valve clamp can also include a closed ring, which is sleeved outside the periphery of the first clamp part and the periphery of the second clamp part, such that the clamping arms can close as needed, and the clamping is tighter. The valve clamp has the advantages of a minimally invasive implantation, a simple manufacture, a low difficulty of operation, good effects, etc.Type: ApplicationFiled: February 15, 2017Publication date: January 3, 2019Applicant: Zhongshan Hospital, Fudan UniversityInventors: Wenzhi Pan, Daxin ZHOU, Junbo GE, Leilei CHENG
-
Patent number: 8591931Abstract: A coronary stent is provided with asymmetric drug releasing controlled coating used in interventional therapy of coronary disease, containing a bare stent and a coating consisting of drug and carrier, the coating is coated onto the outer wall surface of the bare stent, and is multi-layered. The drug concentration in the coating increases in sequence from the outer layer to the inner layer. The drugs used in different layers of the coating may be identical or different, and particularly may be one or more selected from taxol, rapamycin, heparin, docetaxel and a combination thereof. The carrier may be a random (lactide-glycolide) copolymer having a molecular weight of 50,000-200,000. The drug-coated stent of the present invention employs highly effective drugs, enabling a thinnest coating and reducing the vascular irritation. The drug release is regulated by altering the coating manner so as to satisfy the clinical requirement for controlled drug release.Type: GrantFiled: February 14, 2007Date of Patent: November 26, 2013Assignee: Shangdong Intech Medical Technology Co., LtdInventors: Junbo Ge, Shenguo Wang, Jianzhong Bei, Haijun Zhang, Xiangfei Wang, Xiaoxin Shang, Haihong Guo
-
Patent number: 8518429Abstract: An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement.Type: GrantFiled: April 21, 2008Date of Patent: August 27, 2013Assignee: Beijing Amsino Medical Co., Ltd.Inventors: Junbo Ge, Xiaoyi Ma
-
Publication number: 20100247603Abstract: An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement.Type: ApplicationFiled: April 21, 2008Publication date: September 30, 2010Applicant: BEIJING AMSINO MEDICAL CO., LTDInventors: Junbo Ge, Xiaoyi Ma
-
Publication number: 20100168842Abstract: A coronary stent is provided with asymmetric drug releasing controlled coating used in interventional therapy of coronary disease, containing a bare stent and a coating consisting of drug and carrier, the coating is coated onto the outer wall surface of the bare stent, and is multi-layered. The drug concentration in the coating increases in sequence from the outer layer to the inner layer. The drugs used in different layers of the coating may be identical or different, and particularly may be one or more selected from taxol, rapamycin, heparin, docetaxel and a combination thereof. The carrier may be a random (lactide-glycolide) copolymer having a molecular weight of 50,000-200,000. The drug-coated stent of the present invention employs highly effective drugs, enabling a thinnest coating and reducing the vascular irritation. The drug release is regulated by altering the coating manner so as to satisfy the clinical requirement for controlled drug release.Type: ApplicationFiled: February 14, 2007Publication date: July 1, 2010Inventors: Junbo Ge, Shenguo Wang, Jianzhong Bei, Haijun Zhang, Xiangfei Wang, Xiaoxin Shang, Haihong Guo